Mayne Pharma’s response to the novel coronavirus (COVID-19) situation
March 20, 2020
Mayne Pharma continues to closely monitor the COVID-19 outbreak. We are proactively working to protect the health and safety of our employees and maintain an uninterrupted supply of medicines and services to our customers and patients around the world.
We are following the guidance and advice from the U.S. Center for Disease Control and Prevention (CDC), the World Health Organization (WHO), the Australian government and relevant health officials local to Mayne Pharma locations.
Mayne Pharma has established a global steering committee to monitor, develop and execute actions to manage employee health and safety and ensure our sites remain operational with safe supply and distribution of our medicines.
As part of our commitment to contain the spread of this virus, Mayne Pharma has asked for employees to work remotely where they can and have limited access to the operating sites to essential employees and visitors only. We have also restricted business travel, limited in-person interactions with healthcare professionals and are making use of virtual meeting technology where appropriate to continue collaborating with our business partners.
Our industry plays a critical role and we are working hard to maintain production, supply and distribution through this unprecedented global health crisis.